申请人:KISSEI PHARMACEUTICAL CO., LTD.
公开号:US20160115119A1
公开(公告)日:2016-04-28
The present invention is to provide a novel α-substituted glycinamide derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof.
The present invention provides a compound represented by the general formula (I), which has TRPM8 inhibitory effects:
[wherein A
1
represents a C
6-10
aryl and the like, A
2
represents a C
6-10
aryl and the like, X represents CH and the like, Y represents —CR
1
R
2
— and the like, R
1
and R
2
independently represent a hydrogen atom and the like, R
3
and R
4
independently represent a halogen atom and the like, n is 1 or 2], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing diseases or symptoms caused by hyperexcitability or disorder of afferent neurons.
本发明旨在提供一种新型的α-取代甘氨酰胺衍生物,或其药用可接受的盐,包含该衍生物的药物组合物,以及该衍生物的医药用途。
本发明提供了一种由通用公式(I)表示的化合物,该化合物具有TRPM8抑制效果:
[其中A1代表C6-10芳基等,A2代表C6-10芳基等,X代表CH等,Y代表—CR1R2—等,R1和R2独立代表氢原子等,R3和R4独立代表卤素原子等,n为1或2],或其药用可接受的盐。此外,本发明的化合物(I)可作为治疗或预防由于传入神经元的过度兴奋或障碍引起的疾病或症状的药物。